Table 1.
Demographics, sleep characteristics, depressive symptoms in Chicago and Thailand Cohorts.
| Variable | Chicago (N = 193) |
Thailand (N = 282) |
||||
|---|---|---|---|---|---|---|
| Hypoglycemia (N = 140) |
No Hypoglycemia (N = 53) |
p-value | Hypoglycemia (N = 170) |
No Hypoglycemia (N = 112) |
p-value | |
| Age, mean years (SD) | 59.4 (12.4) | 55.1 (13.8) | .047 | 56.4 (11.8) | 54.6 (11.1) | .19 |
| Female, N (%) | 99 (70.7) | 35 (66.0) | .65 | 98 (57.6) | 64 (57.1) | 1 |
| BMI, mean kg/m2 (SD) | 35.5 (8.2) | 36.0 (8.6) | .71 | 28.4 (4.7) | 29.0 (5.6) | .42 |
| Diabetes Duration, mean years (SD) | 15.5 (10.8) | 8.0 (7.9) | <.01 | 13.9 (9.4) | 6.2 (6.4) | <.01 |
| Hemoglobin A1c, Mean (SD) (%) | 7.8 (1.5) | 8.0 (2.1) | .69 | 7.8 (1.6) | 7.7 (1.5) | .38 |
| Insulin Use, N(%) | 92 (65.7) | 16 (30.2) | <.01 | 83 (48.8) | 22 (19.6) | <.01 |
| Sulfonylurea Use, N (%) | 38 (27.1) | 23 (43.4) | .046 | 89 (52.7) | 43 (38.4) | .026 |
| CES-D Score, Mean (SD) | 14.8 (9.6) | 10.3 (6.2) | <.01 | 12.6 (6.5) | 11.1 (6.2) | .055 |
| Antidepressant/antianxiolytic Use, N (%) | 29 (20.7) | 11 (20.8) | 1 | 13 (7.7) | 5 (4.5) | .33 |
| OSA Risk (High) or Diagnosed, N (%) | 83 (59.3) | 36 (67.9) | .35 | 63 (37.3) | 42 (38.2) | .98 |
| Excessive daytime sleepiness N (%) | 43 (30.7) | 15 (28.3) | .88 | 42 (24.7) | 30 (26.8) | .8 |
| PSQI Score, Mean (SD) | 7.2 (4.4) | 5.8 (3.2) | .019 | 8.4 (3.5) | 7.4 (3.6) | .021 |
Missing Data: Diabetes duration (Chicago 1), Sulfonylurea use (Thailand 1), Antidepressant use (Thailand 2), OSA Risk/Diagnosis (Thailand 3), PSQI Score (Thailand 1), Hypoglycemia frequency (Chicago 1, Thailand 1).